ASCO

New data shows that the test could eventually be useful in helping younger women avoid chemotherapy in the neoadjuvant setting.

In the near term, the firm will launch a laboratory-developed, late-stage lung cancer assay out of its lab in Palo Alto. 

Results from the PROMPT registry presented at ASCO showed that 10 to 15 percent of women with variants in genes not linked to ovarian cancer had oophorectomies.

Presentations at this month's ASCO meeting demonstrated how efforts are advancing to determine when and how longitudinal ctDNA testing will be useful for oncologists.

Meeting presentations supported tweaking the clinical interpretation of Genomic Health's Oncotype DX and bolstered Biotheranostics' Breast Cancer Index.

The company reported that its genome-wide methylation approach could detect 77 percent of stage II cancers in its ongoing case-control CCGA study.

Thrive Earlier Detection is banking on targeted detection of frequent cancer mutations, coupled with protein markers, while competitors turn to genome-wide approaches.

The company highlighted growth in demand for its test , and is now ramping up marketing and focusing on its IVD development plans.